Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals stocks (CPRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.14 – a decrease of 4.88% over the previous week. Catalyst Pharmaceuticals employs 74 staff and has a trailing 12-month revenue of around $133.5 million.
How to buy shares in Catalyst Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CPRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Catalyst Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Catalyst Pharmaceuticals?
- Has coronavirus impacted Catalyst Pharmaceuticals shares?
- Catalyst Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Catalyst Pharmaceuticals stock a buy or sell?
- Catalyst Pharmaceuticals performance over time
- Are Catalyst Pharmaceuticals shares over-valued?
- Catalyst Pharmaceuticals's financials
- How volatile are Catalyst Pharmaceuticals shares?
- Does Catalyst Pharmaceuticals pay a dividend?
- Other common questions
How has Coronavirus impacted Catalyst Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, Catalyst Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $6.24, which is 16.51% up on its pre-crash value of $5.21 and 144.71% up on the lowest point reached during the March crash when the stocks fell as low as $2.55.
If you had bought $1,000 worth of Catalyst Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $743.47 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,482.19.
Catalyst Pharmaceuticals stock price (NASDAQ:CPRX)Use our graph to track the performance of CPRX stocks over time.
Catalyst Pharmaceuticals shares at a glance
|Latest market close||$6.24|
|52-week range||$3.27 - $7.58|
|50-day moving average||$6.83|
|200-day moving average||$5.73|
|Wall St. target price||$10.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.39|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Catalyst Pharmaceuticals price performance over time
|1 week (2022-01-07)||-4.88%|
|1 month (2021-12-15)||-9.83%|
|3 months (2021-10-15)||3.48%|
|6 months (2021-07-15)||13.04%|
|1 year (2021-01-15)||78.80%|
|2 years (2020-01-15)||42.14%|
|3 years (2019-01-15)||142.80%|
|5 years (2017-01-13)||403.23%|
Is Catalyst Pharmaceuticals under- or over-valued?
Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Pharmaceuticals's P/E ratio
Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Catalyst Pharmaceuticals shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Pharmaceuticals's EBITDA
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $48.4 million.
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Catalyst Pharmaceuticals financials
|Revenue TTM||$133.5 million|
|Operating margin TTM||36.14%|
|Gross profit TTM||$87.1 million|
|Return on assets TTM||15.15%|
|Return on equity TTM||23.42%|
|Market capitalisation||$676.5 million|
TTM: trailing 12 months
Catalyst Pharmaceuticals share dividends
We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.
Catalyst Pharmaceuticals share price volatility
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $3.27 up to $7.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.2772. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Pharmaceuticals overview
Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc.
Stocks similar to Catalyst Pharmaceuticals
Frequently asked questions
Catalyst Pharmaceuticals in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Catalyst Pharmaceuticals : Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing - Form 8-K
More guides on Finder
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
Pendle (PENDLE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
The ChampCoin (TCC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.